|
1
|
Yamagami W, Nagase S, Takahashi F, Ino K,
Hachisuga T, Aoki D and Katabuchi H: Clinical statistics of
gynecologic cancers in Japan. J Gynecol Oncol.
28(e32)2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
McDonald ME and Bender DP: Endometrial
cancer: Obesity, genetics, and targeted agents. Obstet Gynecol Clin
North Am. 46:89–105. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Yamada A, Sasada T, Noguchi M and Itoh K:
Next-generation peptide vaccines for advanced cancer. Cancer Sci.
104:15–21. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sasada T, Yamada A, Noguchi M and Itoh K:
Personalized peptide vaccine for treatment of advanced cancer. Curr
Med Chem. 21:2332–2345. 2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sakamoto S, Noguchi M, Yamada A, Itoh K
and Sasada T: Prospect and progress of personalized peptide
vaccinations for advanced cancers. Expert Opin Biol Ther.
16:689–698. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kawano K, Tsuda N, Matsueda S, Sasada T,
Watanabe N, Ushijima K, Yamaguchi T, Yokomine M, Itoh K, Yamada A
and Kamura T: Feasibility study of personalized peptide vaccination
for recurrent ovarian cancer patients. Immunopharmacol
Immunotoxicol. 36:224–236. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kawano K, Tsuda N, Waki K, Matsueda S,
Hata Y, Ushijima K, Itoh K, Yamada A and Kamura T: Personalized
peptide vaccination for cervical cancer patients who have received
prior platinum-based chemotherapy. Cancer Sci. 106:1111–1117.
2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Waki K, Yokomizo K, Kawano K, Tsuda N,
Komatsu N and Yamada A: Integrity of plasma DNA is inversely
correlated with vaccine-induced antitumor immunity in ovarian
cancer patients. Cancer Immunol Imunother. 69:2001–2007.
2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Umetani N, Kim J, Hiramatsu S, Reber HA,
Hines OJ, Bilchik AJ and Hoon DS: Increased integrity of free
circulating DNA in sera of patients with colorectal or
periampullary cancer: Direct quantitative PCR for ALU repeats. Clin
Chem. 52:1062–1069. 2006.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Noguchi M, Mine T, Komatsu N, Suekane S,
Moriya F, Matsuoka K, Yutani S, Shichijo S, Yamada A, Toh U, et al:
Assessment of immunological biomarkers in patients with advanced
cancer treated by personalized peptide vaccination. Cancer Biol
Ther. 10:1266–1279. 2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Shirahama T, Muroya D, Matsueda S, Yamada
A, Shichijo S, Naito M, Yamashita T, Sakamoto S, Okuda K, Itoh K,
et al: A randomized phase II trial of personalized peptide vaccine
with low dose cyclophosphamide in biliary tract cancer. Cancer Sci.
108:838–845. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kibe S, Yutani S, Motoyama S, Nomura T,
Tanaka N, Kawahara A, Yamaguchi T, Matsueda S, Komatsu N, Miura M,
et al: Phase II study of personalized peptide vaccination for
previously treated advanced colorectal cancer. Cancer Immunol Res.
2:1154–1162. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Yutani S, Komatsu N, Yoshitomi M, Matsueda
S, Yonemoto K, Mine T, Noguchi M, Ishihara Y, Yamada A, Itoh K and
Sasada T: A phase II study of a personalized peptide vaccination
for chemotherapy-resistant advanced pancreatic cancer patients.
Oncol Rep. 30:1094–1100. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yoshitomi M, Yutani S, Matsueda S, Ioji T,
Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T and Kinoshita H:
Personalized peptide vaccination for advanced biliary tract cancer:
IL-6, nutritional status and pre-existing antigen-specific immunity
as possible biomarkers for patient prognosis. Exp Ther Med.
3:463–469. 2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yoshiyama K, Terazaki Y, Matsueda S,
Shichijo S, Noguchi M, Yamada A, Mine T, Ioji T, Itoh K, Shirouzu
K, et al: Personalized peptide vaccination in patients with
refractory non-small cell lung cancer. Int J Oncol. 40:1492–1500.
2012.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Fucikova J, Moserova I, Urbanova L, Bezu
L, Kepp O, Cremer I, Salek C, Strnad P, Kroemer G, Galluzzi L and
Spisek R: Prognostic and predictive value of DAMPs and
DAMP-associated processes in cancer. Front Immunol.
6(402)2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Waki K, Kawano K, Tsuda N, Ushijima K,
Itoh K and Yamada A: Plasma levels of high-mobility group box 1
during peptide vaccination in patients with recurrent ovarian
cancer. J Immunol Res. 2017(1423683)2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Jin Z and El-Deiry WS: Overview of cell
death signaling pathways. Cancer Biol Ther. 4:139–163.
2005.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Giacona MB, Ruben GC, Iczkowski KA, Roos
TB, Porter DM and Sorenson GD: Cell-free DNA in human blood plasma:
Length measurements in patients with pancreatic cancer and healthy
controls. Pancreas. 17:89–97. 1998.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Cheng J, Tang Q, Cao X and Burwinkel B:
Cell-free circulating DNA integrity based on peripheral blood as a
biomarker for diagnosis of cancer: A systematic review. Cancer
Epidemiol Biomarkers Prev. 26:1595–1602. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhang R, Pu W, Zhang S, Chen L, Zhu W,
Xiao L, Xing C and Li K: Clinical value of ALU concentration and
integrity index for the early diagnosis of ovarian cancer: A
retrospective cohort trial. PLoS One. 13(e0191756)2018.PubMed/NCBI View Article : Google Scholar
|
